Elevation Oncology, Inc.: Nasdaq/NYSE listing notice — Elevation Oncology transfers to Nasdaq Capital Market; granted 180-day bid price cure period

Elevation Oncology, Inc.

Transfer from Nasdaq Global Select to Nasdaq Capital Market effective March 21, 2025.
Company noncompliant with $1.00 minimum bid price for 30 consecutive days as of Sept 2024.
Nasdaq granted additional 180 days, until September 15, 2025, to regain compliance.
To cure, closing bid price must hit $1.00 for 10 consecutive business days by that date.
Company will monitor and consider options including a reverse stock split if needed.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Elevation Oncology, Inc. received a nasdaq extension granted notice regarding minimum bid price.

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price

Exact text from the filing

March 19, 2025, the Nasdaq Listing Qualifications department approved the Company’s request to transfer the listing of the Company’s shares of common stock from The Nasdaq Global Select Market to The Nasdaq Capital Market. The transfer will take effect at the opening of business on March 21, 2025. The transfer of the Company’s listing to The Nasdaq Capital Market is not expected to have any immediate effect on trading in shares of the Company’s common stock. The Company’s shares will continue to trade uninterruptedly under the symbol “ELEV.” The Nasdaq Capital Market operates in substantially

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001558370-25-003305

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.